Blog
About

3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Clinical outcomes of platinum-based chemotherapy according to T790M mutation status in EGFR-positive non-small cell lung cancer patients after initial EGFR-TKI failure.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Emergence of the T790M point mutation in exon 20 of epidermal growth factor receptor (EGFR) is the most common mechanism of resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs). It remains unclear whether the efficacy of platinum-doublet chemotherapy is impacted by the presence of the T790M mutation. The aim of this study is to evaluate the efficacy of platinum-doublet chemotherapy after initial EGFR-TKI failure according to the EGFR T790M in patients with advanced EGFR-mutation-positive non-small cell lung cancer (NSCLC).

          Related collections

          Author and article information

          Journal
          Lung Cancer
          Lung cancer (Amsterdam, Netherlands)
          Elsevier BV
          1872-8332
          0169-5002
          July 2017
          : 109
          Affiliations
          [1 ] Department of Thoracic Oncology, Aichi Cancer Center Hospital, Aichi, Japan. Electronic address: t.yoshida@aichi-cc.jp.
          [2 ] Department of Thoracic Surgery, Aichi Cancer Center Hospital, Aichi, Japan.
          [3 ] Department of Thoracic Oncology, Aichi Cancer Center Hospital, Aichi, Japan.
          [4 ] Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Aichi, Japan.
          Article
          S0169-5002(17)30310-0
          10.1016/j.lungcan.2017.05.001
          28577956

          Comments

          Comment on this article